|
gptkbp:instanceOf
|
gptkb:biotechnology
|
|
gptkbp:acquiredBy
|
gptkb:AstraZeneca
|
|
gptkbp:acquisitionYear
|
2021
|
|
gptkbp:acquisitionYearOfSynageva
|
2015
|
|
gptkbp:businessModel
|
public
|
|
gptkbp:CEO
|
gptkb:Ludwig_Hantson
|
|
gptkbp:focusesOn
|
rare diseases
|
|
gptkbp:foundedYear
|
1992
|
|
gptkbp:founder
|
gptkb:Leonard_Bell
|
|
gptkbp:headquartersLocation
|
gptkb:Boston,_Massachusetts,_United_States
New Haven, Connecticut, United States
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Alexion Pharmaceuticals
|
|
gptkbp:industry
|
gptkb:biotechnology
|
|
gptkbp:listedOn
|
gptkb:S&P_500
|
|
gptkbp:mainTherapeuticArea
|
neurology
hematology
metabolic disorders
|
|
gptkbp:notableAcquisition
|
gptkb:Synageva_BioPharma
|
|
gptkbp:notableCase
|
Soliris pricing controversy
|
|
gptkbp:notableProduct
|
gptkb:Kanuma
gptkb:Soliris
gptkb:Strensiq
gptkb:Ultomiris
|
|
gptkbp:numberOfEmployees
|
~3000
|
|
gptkbp:parentCompany
|
gptkb:AstraZeneca
|
|
gptkbp:publiclyTraded
|
true
|
|
gptkbp:researchInterest
|
orphan drugs
|
|
gptkbp:specializesIn
|
complement inhibition therapies
|
|
gptkbp:stockSymbol
|
gptkb:ALXN
|
|
gptkbp:tradedOn
|
gptkb:NASDAQ
|
|
gptkbp:website
|
https://alexion.com
|
|
gptkbp:bfsParent
|
gptkb:AstraZeneca
|
|
gptkbp:bfsLayer
|
5
|